8EHQ-0197-1303S

8EHQ-91-1303
8997 0000061S
8EF4

PUBLIC COPY

Via Federal Express

January 28, 1997

Document Processing Center (TS-790)
Attention: 8 (e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street SW
Washington, DC 20460

COMPANY SANITIZED

RECEIVED
OPPT NCIC
97 JAN 29 AM 11:13

Dear 8(e) Coordinator:

8EHQ-0791-1303 (Cymoxanil)

and

8EHQ-93-8733 (Substituted Heterocycle)

This letter is to inform you of the results of a recently conducted acute oral toxicity study (LD50) in rats with a R&D proprietary mixture containing these materials. Groups of 5 male and 5 female Crl:CD®BR rats were fasted overnight and then administered the test mixture by intragastric intubation. After dosing, the rats were observed for mortality and clinical signs of toxicity over a 14-day observation period.

The R&D proprietary mixture contained cymoxanil and substituted heterocycle. The rats were dosed at 1000, 3000, 4000, or 5000 mg/kg. Mortality occurred in 0/5, 5/5, 5/5, and 4/5 male rats dosed at 1000, 3000, 4000, and 5000 mg/kg, respectively, and in 3/5, 5/5, 5/5, and 4/5 female rats dosed at 1000, 3000, 4000, and 5000 mg/kg, respectively. Lethargy, tremors, ataxia, and abnormal gait or mobility were observed in surviving male and female rats dosed at 1000 mg/kg. Lethargy and abnormal gait or mobility were observed in surviving male and female rats dosed at 5000 mg/kg. The LD50 was estimated to be 1732 mg/kg for male rats and 566 mg/kg for female rats. The LD50 for male and female rats combined was estimated to be 1311 mg/kg.

Under these experimental conditions, the clinical signs described above appear to be reportable, based upon EPA guidance regarding the reportability of such data under TSCA Section 8(e) criteria.

Substantiation of our confidentiality claim for 8EHQ-93-8733 was included previously with our original filing and still applies.

Sincerely,

RECEIVED
OPPT NCIC
97 FEB -4 AM 8:21

Best Available Copy